Fibroblast growth factor receptor inhibitors in glioma: a narrative review of recent advances.

ABSTRACT: Gliomas are devastating CNS malignancies characterized by extreme molecular heterogeneity and poor prognosis; the fibroblast growth factor receptor (FGFR) signaling axis, which drives proliferation, stemness, and metabolic adaptation, has thus emerged as a crucial therapeutic target. This review systematically synthesizes recent advances in understanding FGFR dysregulation, the clinical application of FGFR inhibitors, and the overriding pharmacological hurdles to achieving effective CNS exposure. FGFR signaling is dysregulated in gliomas by a range of genomic alterations, including mutations, amplifications, and key oncogenic fusions (e.g., FGFR3-TACC3). Moreover, contemporary investigations have demonstrated that novel structural changes in FGFR2 and FGFR3 are frequently linked to an aggr

SUBMITTER: Han M 

PROVIDER: S-EPMC12816223 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature